D
Daniel Aletaha
Researcher at Medical University of Vienna
Publications - 398
Citations - 51111
Daniel Aletaha is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 74, co-authored 298 publications receiving 43215 citations. Previous affiliations of Daniel Aletaha include National Institutes of Health & University of Vienna.
Papers
More filters
Journal ArticleDOI
Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology
Andreas Kerschbaumer,Josef S Smolen,Harald Herkner,Tijen Stefanova,Eva Chwala,Daniel Aletaha +5 more
TL;DR: A meta-analysis comparing primary efficacy outcomes of phase 2 and phase 3 randomized controlled trials in rheumatoid arthritis and psoriatic arthritis shows that phase 2 studies consistently overestimate the effect sizes anticipated in subsequent phase 3 trials.
Journal ArticleDOI
A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.
Kulveer Mankia,Heidi J. Siddle,Andrea Di Matteo,Deshire Alpizar-Rodriguez,Joel Kerry,Andreas Kerschbaumer,Daniel Aletaha,Paul Emery +7 more
TL;DR: In this article, a literature search and systematic literature review (SLR) was conducted to identify risk factors in individuals at risk of RA using Medline, Embase, PubMed and Central databases.
Journal ArticleDOI
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial
Daniel Mrak,Daniela Sieghart,Elisabeth Simader,Selma Tobudic,Helga Radner,Peter Mandl,Lisa Göschl,Maximilian Koblischke,Nikolaus Hommer,Angelika Wagner,Margareta Mayer,Lorenz Schubert,L. Hartl,Karin Kozbial,Philipp Hofer,Felix Kartnig,Thomas Hummel,Andreas Kerschbaumer,Thomas Deimel,Antonia Puchner,Venugopal Gudipati,Renate Thalhammer,P Munda,Keziban Uyanik-Ünal,Andreas Zuckermann,Gottfried Novacek,Thomas Reiberger,Erika Garner-Spitzer,Roman Reindl-Schwaighofer,Renate Kain,Stefan Winkler,Josef S Smolen,Karin Stiasny,H. Fischer,Thomas Perkmann,Helmuth Haslacher,Markus Zeitlinger,Ursula Wiedermann,Judith H. Aberle,Daniel Aletaha,Leonhard X. Heinz,Michael Bonelli +41 more
TL;DR: In this paper , the authors performed a single center, 1:1 randomized blinded clinical trial to determine the best vaccination strategy for immunosuppressed patients with CoV-19 vaccination, where patients who failed to seroconvert upon two mRNA vaccinations (BNT162b2 or mRNA-1273) were randomized to receive either a third dose of the same mRNA or the vector vaccine.
Journal ArticleDOI
American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision
Paul Studenic,Daniel Aletaha,Maarten de Wit,Tanja Stamm,Farideh Alasti,Diane Lacaille,Josef S Smolen,David T. Felson +7 more
TL;DR: Using the Boolean 2.0 criteria classifies more patients as achieving remission and increases the agreement with index-based remission criteria without jeopardizing predictive value for radiographic or functional outcomes.
Journal ArticleDOI
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
Christian Dejaco,Andreas Kerschbaumer,Daniel Aletaha,Milena Bond,Elvis Hysa,Dario Camellino,Lisa Ehlers,Andy Abril,Simone Appenzeller,Maria C. Cid,Bhaskar Dasgupta,Christina Duftner,Peter C. Grayson,Bernhard Hellmich,Alojzija Hočevar,Tanaz A. Kermani,Eric L. Matteson,Susan P Mollan,Lorna Neill,Cristina Ponte,Carlo Salvarani,Sebastian E. Sattui,Wolfgang A. Schmidt,Philip Seo,Josef S Smolen,Jens Thiel,Carlos Enrique Toro-Gutiérrez,Madeline Whitlock,Frank Buttgereit +28 more
TL;DR: In this article , the authors present the first T2T recommendations for giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) based on evidence and expert opinion, with consensus obtained through voting.